HS-173newfeatured
WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#:406355
CAS#:1276110-06-5
Description:HS-173 is a potent PI3Kα inhibitor with potential anticancer activity. HS-173 inhibited the PI3K signaling pathway, and showed anti-proliferative effects on cancer cells. Also, HS-173 induced cell cycle arrest at the G(2)/M phase and apoptosis. In addition, HS-173 decreased the expression HIF-1α and VEGF which play an important role in angiogenesis. This effect was confirmed by the suppression of tube formation and migration assay in vitro. Furthermore, HS-173 diminished blood vessel formation in the Matrigel plug assay in mice. Therefore, HS-173 is considered as a novel drug candidate to treat cancer patients.
Price and Availability
HS-173, purity > 98%, is in stock. The same day shipping out after order is received.
Chemical Structure
Theoretical Analysis
MedKoo Cat#: 406355Name: HS-173CAS#: 1276110-06-5Chemical Formula: C21H18N4O4SExact Mass: 422.10488Molecular Weight: 422.46Elemental Analysis: C, 59.70; H, 4.29; N, 13.26; O, 15.15; S, 7.59
Synonym:HS173; HS 173; HS-173.
IUPAC/Chemical Name:ethyl 6-(5-(phenylsulfonamido)pyridin-3-yl)imidazo[1,2-a]pyridine-3-carboxylate
InChi Key:SEKOTFCHZNXZMM-UHFFFAOYSA-N
InChi Code:InChI=1S/C21H18N4O4S/c1-2-29-21(26)19-13-23-20-9-8-15(14-25(19)20)16-10-17(12-22-11-16)24-30(27,28)18-6-4-3-5-7-18/h3-14,24H,2H2,1H3
SMILES Code:O=C(C1=CN=C2C=CC(C3=CC(NS(=O)(C4=CC=CC=C4)=O)=CN=C3)=CN21)OCC
Technical Data
Additional Information
References
1: Son MK, Ryu YL, Jung KH, Lee H, Lee HS, Yan HH,Park HJ, Ryu JK, Suh JK, Hong S, Hong SS. HS-173, a novel PI3Kinhibitor, attenuates the activation of hepatic stellate cells in liverfibrosis. Sci Rep. 2013 Dec 11;3:3470. doi: 10.1038/srep03470. PubMedPMID: 24326778; PubMed Central PMCID: PMC3858860.
2: Lee H, Kim SJ, Jung KH, Son MK, Yan HH, Hong S, Hong SS. A novelimidazopyridine PI3K inhibitor with anticancer activity in non-smallcell lung cancer cells. Oncol Rep. 2013 Aug;30(2):863-9. doi:10.3892/or.2013.2499. Epub 2013 May 27. PubMed PMID: 23708425.
3: Jung KH, Ryu YL, Lee HS, Lee H, Son MK, Yan HH, Hong SW, Ryu JK, HongS, Suh JK, Hong SS. A novel PI3K inhibitor alleviates fibrotic responsesin fibroblasts derived from Peyronie"s plaques. Int J Oncol. 2013Jun;42(6):2001-8. doi: 10.3892/ijo.2013.1905. Epub 2013 Apr 16. PubMedPMID: 23588860.
4: Yun SM, Jung KH, Lee H, Son MK, Seo JH, Yan HH, Park BH, Hong S, HongSS. Synergistic anticancer activity of HS-173, a novel PI3K inhibitor incombination with Sorafenib against pancreatic cancer cells. Cancer Lett.2013 May 1;331(2):250-61. doi: 10.1016/j.canlet.2013.01.007. Epub 2013Jan 20. PubMed PMID: 23340175.
5: Lee H, Jung KH, Jeong Y, Hong S, Hong SS. HS-173, a novelphosphatidylinositol 3-kinase (PI3K) inhibitor, has anti-tumor activitythrough promoting apoptosis and inhibiting angiogenesis. Cancer Lett.2013 Jan 1;328(1):152-9. doi: 10.1016/j.canlet.2012.08.020. Epub 2012Aug 26. PubMed PMID: 22929971.
